SPRB
Spruce Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$57.88
+0.29%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.6x
Market Cap
$166.35M
MomentumView details →
1D Return
+0.29%
YTD Return
−33.38%
RSI (14)
57.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.6x
Market Cap
$166.35M
RSI (14)
57.5
MomentumView details →
1D Return
+0.29%
YTD Return
−33.38%
SummaryUpdated Jun 1, 2026
Spruce Biosciences, Inc. (NASDAQ:SPRB) is a biopharmaceutical company founded in 2014 and headquartered in Daly City, California. The company went public in October 2020 and has undergone a significant strategic transformation. Originally focused on developing treatments for congenital adrenal hyperplasia (CAH), Spruce pivoted in 2024 to acquire and develop Tralesinidase Alfa, an enzyme replacement therapy for a rare pediatric neurodegenerative disease called MPS IIIB (Mucopolysaccharidosis IIIB or Sanfilippo syndrome type B).
Similar companies
Latest newsMore news →
Spruce Biosciences launched MPS3BStudy.com, an online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB), enabling them to learn about and register interest in a related study.9d agoSpruce Biosciences hired Adrian Quartel as chief medical officer.14d agoCure Sanfilippo Foundation and the National MPS Society agreed to make a combined $5.5 million strategic investment in Spruce Biosciences.23d ago